Lookup NU author(s): Dr Robert Tinnion,
Professor Nicholas Embleton
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Alkaline phosphatase (ALP) is regularly measured in clinical practice. Changes in serum levels are observed in a number of clinical conditions. In neonatology, it has been proposed as a useful marker for both a diagnosis and an indication of the severity of metabolic bone disease (MBD) in infants born preterm. Nutritional practices, aimed at reducing the occurrence or severity of MBD, have led to ALP being proposed as a stand-alone means of monitoring treatment. The current evidence does not support this use: ALP only achieves usefulness in a diagnostic and monitoring capacity when combined with other serum and imaging techniques.
Author(s): Tinnion RJ, Embleton ND
Publication type: Article
Publication status: Published
Journal: Archives of Disease in Childhood: Education and Practice Edition
Print publication date: 03/07/2012
ISSN (print): 1743-0585
ISSN (electronic): 1743-0593
Publisher: BMJ Group
Altmetrics provided by Altmetric